title: Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.
abstract: In the present work, the characterization of the biotransformation and bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant (Acomplia) is described. Rimonabant was approved in Europe in 2006 for the treatment of obesity but was withdrawn in 2008 because of a significant drug-related risk of serious psychiatric disorders. The aim of the present work is to characterize the biotransformation and potential bioactivation pathways of rimonabant in vitro in human and rat liver microsomes. The observation of a major iminium ion metabolite led us to perform reactive metabolite trapping, covalent binding to proteins, and time-dependent inhibition of cytochrome P450 3A4 studies. The major biotransformation pathways were oxidative dehydrogenation of the piperidinyl ring to an iminium ion, hydroxylation of the 3 position of the piperidinyl ring, and cleavage of the amide linkage. In coincubations with potassium cyanide, three cyanide adducts were detected. A high level of covalent binding of rimonabant in human liver microsomes was observed (920 pmol equivalents/mg protein). In coincubations with potassium cyanide and methoxylamine, the covalent binding was reduced by approximately 40 and 30%, respectively, whereas GSH had no significant effect on covalent binding levels. Rimonabant was also found to inhibit cytochrome P450 3A4 irreversibly in a time-dependent manner. In view of these findings, it is noteworthy that, to date, no toxicity findings related to the formation of reactive metabolites from rimonabant have been reported.
authors: CVGI iMED DMPK, AstraZeneca R&D Mölndal, SE-43183 Mölndal, Sweden. moa.andresen.bergstrom@astrazeneca.com
authors: Moa Andresen
authors: MA
authors: Bergström
authors: Emre M
authors: EM
authors: Isin
authors: Neal
authors: N
authors: Castagnoli
authors: Claire E
authors: CE
authors: Milne
mesh_terms: D000818:Animals; D001711:Biotransformation; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D006801:Humans; D006898:Hydroxylamines / Q000494:pharmacology; D008862:Microsomes, Liver / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D010880:Piperidines / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D011190:Potassium Cyanide / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011720:Pyrazoles / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077285:Rimonabant
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D006898:Hydroxylamines; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D003577:Cytochrome P-450 Enzyme System; C005214:methoxyamine; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D011190:Potassium Cyanide; D000077285:Rimonabant